Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-title" }, "data": [ { "type": "Grant", "id": "765", "attributes": { "award_id": "2050336", "title": "A Collaborative Regional Alliance to Prepare STEM Secondary Teachers for Service in Rural, High-Need Schools and School Districts", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)" ], "program_reference_codes": [], "program_officials": [ { "id": 1793, "first_name": "Kimberly", "last_name": "Tanner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-03-01", "end_date": "2026-02-28", "award_amount": 739743, "principal_investigator": { "id": 1798, "first_name": "Corin D", "last_name": "Slown", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 394, "ror": "", "name": "University Corporation at Monterey Bay", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 1794, "first_name": "Sagayamary V", "last_name": "Rayappan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 1795, "first_name": "Dennis", "last_name": "Kombe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 1796, "first_name": "Sara K", "last_name": "Decelle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 1797, "first_name": "Jaye", "last_name": "Luke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 394, "ror": "", "name": "University Corporation at Monterey Bay", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project aims to serve the national need of preparing qualified and innovative STEM teachers among a rural population that has been disproportionately impacted by the COVID-19 pandemic. Transforming the early experiences of future teachers can help to ensure the Nation has qualified STEM educators capable of inspiring and preparing the future STEM workforce. The project intends to do so by recruiting, preparing, and supporting a diverse group of undergraduate STEM majors to become highly skilled STEM secondary teachers. These future teachers will include community college students and lower division students who represent the region's demographic diversity. The project intends to prepare these students to serve as highly qualified middle and high school STEM teachers in rural, high-need schools and school districts. To recruit, prepare, and support these STEM students, project partners will coordinate two teacher preparation pathways that emphasize early STEM research and inquiry experiences.This project at California State University Monterey Bay, a Hispanic-Serving Institution (HSI) will leverage a regional alliance between three other post-secondary HSIs (Cabrillo College, Hartnell College, and Monterey Peninsula College) and the County Office of Education, representing 24 school districts in California's Central Coast region. Responding to consequences of the COVID-19 pandemic, the project will provide future teachers with online instruction and prepare them to be skilled online and in-person teachers. For example, it will help future STEM teachers develop their capacity to facilitate STEM inquiry in ways that integrate digital citizenship and technology. It aims to recruit, support, and prepare 30 new STEM teachers who will be recruited from undergraduate STEM majors (including biology, computer science, environmental science, marine science, mathematics, or statistics) at California State University Monterey Bay and partnering community colleges. The students will receive scholarship support for their senior year and post-baccalaureate STEM teacher credentialing year. In addition, mid-career STEM professionals will be recruited and receive stipend support to complete the one-year post-baccalaureate STEM teacher credentialing program. The Next Generation Science Standards Regional Collaborative Teacher Network coordinated by the County Office of Education will provide the prospective teachers with access to an early, inclusive STEM community of practice of current in-service teachers who are implementing best practices for STEM instruction and student learning. Early STEM inquiry, teaching, and mentored research opportunities will integrate active learning and culturally responsive pedagogy to build early social capital and create a diverse STEM teacher community. Project outcomes have potential to provide a model for the California Community College system (115 colleges) and California State University system (23 universities) to broaden the applicant pool of highly qualified STEM teachers. Dissemination of the model and strategies will help to address short- and long-term teacher shortages through an expanded STEM teacher preparation pipeline. Qualified and innovative STEM teachers in rural districts will have critical roles in developing the STEM workforce to meet emerging critical needs. This Track 1: Scholarships and Stipends project is supported through the Robert Noyce Teacher Scholarship Program (Noyce). The Noyce program supports talented STEM undergraduate majors and professionals to become effective K-12 STEM teachers and experienced, exemplary K-12 teachers to become STEM master teachers in high-need school districts. It also supports research on the persistence, retention, and effectiveness of K-12 STEM teachers in high-need school districts. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "828", "attributes": { "award_id": "2055735", "title": "A Collaborative Approach to Work-Based Learning in Biotechnology: Building Inclusive Lab Environments", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)" ], "program_reference_codes": [], "program_officials": [ { "id": 1973, "first_name": "Virginia", "last_name": "Carter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-05-15", "end_date": "2024-04-30", "award_amount": 262964, "principal_investigator": { "id": 1974, "first_name": "Naledi M", "last_name": "Saul", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 432, "ror": "", "name": "University of California-San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 432, "ror": "", "name": "University of California-San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "There is a renewed sense of urgency to develop a more diverse workforce in STEM-related fields. This project focuses on community college students from groups that are not yet equitably represented in STEM. These communities have also been disproportionately impacted by the COVID-19 pandemic. Most workforce interventions to prepare students for technical positions have been based on the premise that the students simply need targeted skill training and tips on behavioral norms to be successful in these workplace cultures. This “student deficit” model puts the burden on the newcomer to navigate a work environment that is often inherently biased against people of color, women, and individuals from groups that are underrepresented in the sciences. However, as leading-edge organizations are recognizing the value of diversity, they are also realizing that they have a role to play in establishing an inclusive workplace culture. This project aims to foster the professional development of students, faculty, industry managers, and academic researchers in inclusive workplace practices. The project expects that these practices can seed true cultural change and prepare a more diverse, inclusive, and productive United States biotechnology workforce.This project at City College of San Francisco is a collaboration with the Office of Career and Professional Development at the University of California, San Francisco. Its overall goal is to build more inclusive workplace environments for community college students pursuing biotechnology education and careers. The project plans to address issues of diversity in the scientific workforce by 1) teaching industry managers and academic researchers practical ways to supervise, mentor and train future scientists inclusively and effectively, and 2) helping community college students and their instructors navigate the scientific workplace to identify inclusive workplaces and navigate barriers to inclusivity. It builds on prior work that has led to the development of a published framework for inclusive workplace practices in research laboratories, a comprehensive inclusive academic mentor and intern training, and a guided internship program that includes formative assessments and coaching. In collaboration with the California Life Sciences Institute, an organization representing hundreds of biotechnology companies, the project will invest significant resources in developing new frameworks, tools, and curriculum tailored to the needs of the biotechnology industry. Additionally, the project seeks to disseminate the trainings to other community colleges and academic research institutions. This project is funded by the Advanced Technological Education program that focuses on the education of technicians for the advanced-technology fields that drive the nation's economy. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "829", "attributes": { "award_id": "2055309", "title": "A Collaborative Approach to Work-Based Learning in Biotechnology: Building Inclusive Lab Environments", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Education and Human Resources (EHR)" ], "program_reference_codes": [], "program_officials": [ { "id": 1975, "first_name": "Virginia", "last_name": "Carter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-05-15", "end_date": "2024-04-30", "award_amount": 275596, "principal_investigator": { "id": 1977, "first_name": "James B", "last_name": "Lewis", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 431, "ror": "https://ror.org/03181bn25", "name": "City College of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 1976, "first_name": "Karen", "last_name": "Leung", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 431, "ror": "https://ror.org/03181bn25", "name": "City College of San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "There is a renewed sense of urgency to develop a more diverse workforce in STEM-related fields. This project focuses on community college students from groups that are not yet equitably represented in STEM. These communities have also been disproportionately impacted by the COVID-19 pandemic. Most workforce interventions to prepare students for technical positions have been based on the premise that the students simply need targeted skill training and tips on behavioral norms to be successful in these workplace cultures. This “student deficit” model puts the burden on the newcomer to navigate a work environment that is often inherently biased against people of color, women, and individuals from groups that are underrepresented in the sciences. However, as leading-edge organizations are recognizing the value of diversity, they are also realizing that they have a role to play in establishing an inclusive workplace culture. This project aims to foster the professional development of students, faculty, industry managers, and academic researchers in inclusive workplace practices. The project expects that these practices can seed true cultural change and prepare a more diverse, inclusive, and productive United States biotechnology workforce.This project at City College of San Francisco is a collaboration with the Office of Career and Professional Development at the University of California, San Francisco. Its overall goal is to build more inclusive workplace environments for community college students pursuing biotechnology education and careers. The project plans to address issues of diversity in the scientific workforce by 1) teaching industry managers and academic researchers practical ways to supervise, mentor and train future scientists inclusively and effectively, and 2) helping community college students and their instructors navigate the scientific workplace to identify inclusive workplaces and navigate barriers to inclusivity. It builds on prior work that has led to the development of a published framework for inclusive workplace practices in research laboratories, a comprehensive inclusive academic mentor and intern training, and a guided internship program that includes formative assessments and coaching. In collaboration with the California Life Sciences Institute, an organization representing hundreds of biotechnology companies, the project will invest significant resources in developing new frameworks, tools, and curriculum tailored to the needs of the biotechnology industry. Additionally, the project seeks to disseminate the trainings to other community colleges and academic research institutions. This project is funded by the Advanced Technological Education program that focuses on the education of technicians for the advanced-technology fields that drive the nation's economy. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11202", "attributes": { "award_id": "1R42CA275665-01A1", "title": "A cloud-based digital health navigation program for colorectal cancer screening", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 4683, "first_name": "Ming", "last_name": "Zhao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-04-01", "end_date": "2024-03-31", "award_amount": 397979, "principal_investigator": { "id": 24889, "first_name": "David P", "last_name": "Miller", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1149, "ror": "", "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1998, "ror": "", "name": "DIGITAL HEALTH NAVIGATION SOLUTIONS, LLC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or embarrassing. Busy clinicians report a lack of time to deliver preventive care, and many clinicians only discuss colonoscopy. Lastly, healthcare systems lack strategies to reach out to patients independent of a scheduled medical visit. Disruptions caused by COVID19 also have led to a decrease in the use of preventive services. To address these multilevel barriers, our team has developed and tested a tablet-based digital health navigator for colorectal cancer screening called mPATH™ (mobile Patient Technology for Health). mPATH™ determines if patients are due for CRC screening, educates them about their options, and lets them request a screening test directly via the program. In a randomized controlled trial conducted in primary care practices, mPATH™ doubled the proportion of patients who completed CRC screening and had excellent usability ratings. However, we have learned that our tablet-based model of mPATH™ is difficult to scale as it requires on-site training and changes to workflows. The goal of this Fast Track STTR proposal is to develop and test a cloud-based version of mPATH™ that patients can use at home independent of a scheduled medical visit. Patients will access mPATH™ on their own devices using a hyperlink sent via text message or patient portal. The cloud version of mPATH™ will have the proven effective content of the tablet version, including the ability to request a screening test directly via the program. mPATH™ will then share this information with the patient’s healthcare organization so screening can be arranged. This cloud-based version will be highly scalable, have broad reach, and be easy to support, making it a commercially viable product. To accomplish this goal, the work of this proposal will: (1) create a culturally appropriate and engaging cloud-based version of mPATH™ by leveraging input from community members, an expert Scientific Advisory Committee, and feedback from users; (2) determine the feasibility of the cloud-based mPATH™-CRC web app in a highly pragmatic pilot trial conducted in a large health system; (3) test the reach and effectiveness of the mPATH™ web app in two different healthcare settings: a large health system, and an Accountable Care Organization that includes rural Federally Qualified Health Centers; and (4) determine the value generated by mPATH™ in each healthcare setting. This Fast Track STTR will provide information that is critical to mPATH™’s future commercialization by demonstrating its reach into diverse populations, its effectiveness in increasing screening, and the value it generates to potential future customers. If successful, mPATH™ will fill a critical need for a commercially available, easily scalable solution for colorectal cancer screening and potentially other preventive services.", "keywords": [ "Address", "Adult", "Advisory Committees", "Age", "American", "COVID-19", "Cancer Etiology", "Caring", "Cessation of life", "Colonoscopy", "Colorectal Cancer", "Communities", "Devices", "Effectiveness", "Electronics", "Eligibility Determination", "Ensure", "Environment", "Ethnic Origin", "Feces", "Federally Qualified Health Center", "Feedback", "Focus Groups", "Future", "Goals", "Health Technology", "Health system", "Healthcare Systems", "Home", "Knowledge", "Learning", "Medical", "Modeling", "Outcome", "Patients", "Phase", "Population Heterogeneity", "Preventive care", "Preventive service", "Publications", "Randomized Controlled Trials", "Reporting", "Risk", "Rural", "Schedule", "Site", "Small Business Technology Transfer Research", "Source", "Stream", "Subgroup", "Tablets", "Technology", "Testing", "Text", "Text Messaging", "Time", "Training", "United States", "Universities", "Update", "Visit", "Work", "accountable care organization", "aged", "barrier to care", "cloud based", "colorectal cancer screening", "commercialization", "cost", "digital", "digital health", "effectiveness testing", "empowerment", "forest", "health care service organization", "health care settings", "health disparity", "innovation", "medical schools", "member", "outreach", "patient portal", "pilot trial", "primary care practice", "primary outcome", "programs", "response", "screening", "screening guidelines", "screening services", "secondary analysis", "uptake", "usability", "web app" ], "approved": true } }, { "type": "Grant", "id": "15241", "attributes": { "award_id": "2R01NR016732-06", "title": "A clinician-in-the-loop smart environment to support management of chronic health conditions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 31607, "first_name": "Karen Marie", "last_name": "Mcnamara", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-08", "end_date": "2029-05-31", "award_amount": 418620, "principal_investigator": { "id": 31826, "first_name": "Diane Joyce", "last_name": "Cook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31827, "first_name": "Roschelle", "last_name": "Fritz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT As the population of individuals 65+ grows, so too will the number of individuals who struggle to manage chronic health conditions. Exacerbations, or sudden symptom worsening, of chronic conditions place a burden on the health care system and cause decreased quality of life and accelerated decline. Forecasting health exacerbations can prevent life-threatening events or limit their impact. The long-term goal of this work is to create a clinician-in-the-loop (CIL) smart environment that empowers individuals in managing their chronic health conditions. Our proposed CIL framework partners clinical expertise with pervasive computing and machine learning. In this system, sensor data are collected continuously by ambient and wearable sensors. Our ML algorithms extract behavior markers to show to a clinician. Behavior changes are detected due to internal (i.e., condition exacerbation) or external (i.e., wildfire smoke, shutdown due to COVID-19 pandemic) events. Trained by clinicians, prediction of future condition exacerbations and health states are generated with corresponding reliability scores. Correspondingly, clinicians will provide summaries of observed behavior, reasons to confirm likely exacerbations, and recommendations to prevent health events. These summaries are used to train a language model that will provide interactive explanations of future data and ML predictions. Data are collected continuously by ambient sensors in the smart home and wearable sensors in Apple watches to validate the findings and provide more complete monitoring. From smartwatch sensors, we will analyze the predictive relationship between external events, social determinants of health, socialization, environment quality, behavior, and health state. The result of these steps is an automated technology that can assist with self-management of chronic conditions and monitor the impact of interventions. The proposed aims will be validated using data collected in our prior study for n=44 older adults and in a new data collection with n=20 older adults. Participants in the restrospective study with historic data and prospective study with new data will be older adults age 50+ living in independent homes who are managing one or more chronic health conditions. Expanding the smart environment to encompass ambient sensors and wearable sensors increases the accessibility of the technology for underserved communities and, when used in combination, improves model robustness through joint prediction. Although clinical oversight of patient health will always be valuable, the technology can provide an “informatics triage” that allows a clinician to remotely monitor a greater number of individuals at a time and provide valuable information to the individual to assist in self-management. Outcomes of this proposed study include open-source software for forecasting condition exacerbations, software to train language models from clinician input, and the corresponding trained models; results of analyses linking external influences, socialization, behavior, and health; apps for collecting ambient and wearable data; and data that will be prepped for integration into the NIH RWDP platform.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7352", "attributes": { "award_id": "3U19AI142731-02S1", "title": "A CETR-based partnership accelerator for rapid drug development targeting SARS-CoV-2 and pan-CoVs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22535, "first_name": "Maureen J.", "last_name": "Beanan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-25", "end_date": "2021-04-30", "award_amount": 619850, "principal_investigator": { "id": 23143, "first_name": "David S", "last_name": "Perlin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1487, "ror": "https://ror.org/008zj0x80", "name": "Hackensack University Medical Center", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1487, "ror": "https://ror.org/008zj0x80", "name": "Hackensack University Medical Center", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "The unprecedented COVID-19 global health crisis is fueled by the absence of an effective vaccine and no specific antiviral drugs. Consequently, major research efforts have focused on identifying efficacious therapies. The most effective short-term solution is repurposing and repositioning of approved drugs or clinical-stage drug candidates, as this approach shortens the time to the clinic. Furthermore, as there are no drugs against any zoonotic coronaviruses associated with human respiratory infections, pan-coronavirus drug regimens are vital to counter future outbreaks. To best address this urgency, a drug development Accelerator has been established as a formal partnership between our NIH Center of Excellence in Translational Research (CETR) and Merck and Co., Inc., a global leader in the discovery and development of antiviral drugs. The CETR program, which is focused on novel and repositioned drugs against high-threat bacterial infections, provides a comprehensive platform for drug discovery. Merck brings a full complement of approved antiviral drugs and advanced candidates for repurposing and repositioning, with an emphasis on novel nucleoside and protease inhibitors. Firstly, small molecule compounds representing both FDA approved drugs and clinical stage drug candidates discovered against other viruses will be evaluated in viral cytopathic and neutralization assays to assess inhibition of SARS- CoV-2. Lead candidates will be assessed for EC50/90/CC50 values, ADME pharmacokinetics, and safety to determine their potential for immediate use in therapy. If data supports a robust therapeutic window, then repurposed compound(s) will be submitted for an IND under FDA EUA. A rodent model utilizing SARS-CoV-2 infection will be used to assess in vivo PK/PD parameters supporting clinical dose ranging and safety margins. Secondly, a pan-coronavirus drug development candidate will be identified from either drug repositioning or from Merck’s focused compound libraries for existing antiviral classes discovered against other conserved viral targets, as well as new lead series to host and viral targets representing >65 mechanisms of action. These compounds will be screened in a high throughput virus challenge assay. SAR will benefit from the multi-million compound Merck sample collection via in silico substructure and similarity searches. Lead compounds will be assessed for robust in vivo therapeutic efficacy against SARS-CoV-2; metabolic stability, toxicity, ADME, rodent tolerability; pharmacologic properties consistent with QD or BID dosing, and acceptable safety margins supportive of initiation of first in human clinical studies. The ultimate goal is the identification of development candidates that can enter preclinical IND enabling safety derisking studies. This is an unprecedented public-private partnership for drug discovery The goal of this drug Accelerator is to identify a repurposed compound(s) that can treat COVID-19 patients within 4-6 months and by the end of Year 2, identify candidates with pan-coronavirus efficacy that can enter preclinical IND-enabling and derisking studies.", "keywords": [ "2019-nCoV", "Address", "Advanced Development", "Animal Model", "Anti-Infective Agents", "Antiviral Agents", "Authorization documentation", "Bacterial Infections", "Biological Assay", "COVID-19", "COVID-19 pandemic", "Cells", "Chemicals", "Clinic", "Clinical", "Clinical Research", "Clinical Trials", "Collection", "Complement", "Coronavirus", "Data", "Development", "Disease Outbreaks", "Dose", "Drug Kinetics", "Emergency Situation", "Enzymes", "Excretory function", "FDA approved", "Future", "Goals", "Hospitals", "Human", "In Vitro", "Infection", "Lead", "Libraries", "Metabolic", "Metabolism", "Middle East Respiratory Syndrome", "Modeling", "Patients", "Pharmaceutical Preparations", "Pharmacodynamics", "Pharmacology", "Pharmacotherapy", "Plasma", "Property", "Protease Inhibitor", "Regimen", "Research", "Respiratory Tract Infections", "Rodent", "Rodent Model", "SARS coronavirus", "Safety", "Structure-Activity Relationship", "Therapeutic", "Time", "Toxic effect", "Translational Research", "Treatment Efficacy", "United States National Institutes of Health", "Vaccines", "Viral", "Viral Proteins", "Virus", "Zoonoses", "absorption", "base", "clinical development", "coronavirus disease", "drug candidate", "drug development", "drug discovery", "first-in-human", "global health", "in silico", "in vivo", "interest", "lead candidate", "lead series", "novel", "novel coronavirus", "nucleoside inhibitor", "pandemic disease", "patient population", "pharmacokinetics and pharmacodynamics", "pre-clinical", "preclinical development", "public-private partnership", "remdesivir", "response", "sample collection", "small molecule", "translational research program" ], "approved": true } }, { "type": "Grant", "id": "7240", "attributes": { "award_id": "3U42OD010924-21S1", "title": "A Carolina Center to Characterize and Maintain Mutant Mice", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 9933, "first_name": "Oleg", "last_name": "Mirochnitchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1999-09-30", "end_date": "2025-02-28", "award_amount": 290862, "principal_investigator": { "id": 12180, "first_name": "TERRY R", "last_name": "MAGNUSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "For decades, the mouse has been the premier animal model for studies of human disease, providing the opportunity to explore experimental questions that are intractable for direct study in humans. As a result, key insights have been obtained for a variety of clinical conditions. Spurred by advances in technology and international efforts to systematically knock out all of the protein coding genes in the genome, the number of genetically engineered mice has expanded rapidly in the past 20 years. The responsibility for maintenance and distribution of mutant mice was initially placed on individual investigators, which was a tremendous burden in terms of cost, labor and space. In 1999, the NIH recognized the need for a resource to protect the investment in mutant mouse strains and ensure open access to all biomedical researchers and established the Mutant Mouse Regional Resource Centers (MMRRC). Since 1999, the central goal of the MMRRC-UNC has been to work collectively with MMRRC consortium partners to develop and maintain high standards for importation, rederivation, cryopreservation, and distribution of mutant mouse strains to biomedical investigators. The MMRRC- UNC will continue to contribute to the goals of the Consortium in the next project period by implementing the following Specific Aims devoted to continuing its successful role as a cryoarchive and distribution center and incorporating research goals that synergize with and extend the value of the resource: 1) Streamline and improve operating procedures to increase importation, distribution, and cryoarchiving of mouse strains. 2) Establish a comprehensive cryoarchive for the Collaborative Cross (CC) resource. 3) Develop and disseminate computational tools for mouse genotyping and genomics research, which will enhance phenotypic reproducibility. 4) Examine the effect of paternal age and epigenetics on mutation rate.", "keywords": [ "Address", "Animal Model", "Applied Research", "Archives", "Biocompatible Materials", "Biomedical Research", "Cell Separation", "Clinical", "Cloning", "Code", "Communities", "Complement", "Cryopreservation", "Data", "Deposition", "Development", "Embryo", "Ensure", "Environment", "Epigenetic Process", "Fee-for-Service Plans", "Funding", "Gene Targeting", "Genes", "Genetic", "Genetic Engineering", "Genetic Research", "Genetically Engineered Mouse", "Genome", "Genomics", "Genotype", "Germ Cells", "Goals", "Health", "Human", "Human Development", "Individual", "Informatics", "International", "Investments", "Knock-out", "Knowledge", "Maintenance", "Marketing", "Mission", "Modeling", "Mouse Strains", "Mus", "Mutagenesis", "Mutant Strains Mice", "Mutation", "Paternal Age", "Phenotype", "Policies", "Procedures", "Process", "Proteins", "Public Health", "Quality Control", "Reproducibility", "Research", "Research Personnel", "Resources", "Role", "Scientist", "Services", "Study models", "System", "Technology", "Testing", "Transgenic Organisms", "United States", "United States National Institutes of Health", "Work", "complement resource", "computerized tools", "cost", "embryo cryopreservation", "embryonic stem cell", "high risk", "high standard", "human disease", "improved", "insight", "mouse genetics", "new technology", "pathogen", "preservation", "programs", "repository", "sperm quality", "tool" ], "approved": true } }, { "type": "Grant", "id": "5902", "attributes": { "award_id": "3U42OD010924-22S1", "title": "A Carolina Center to Characterize and Maintain Mutant Mice", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 20183, "first_name": "Oleg", "last_name": "Mirochnitchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1999-09-30", "end_date": "2025-02-28", "award_amount": 499997, "principal_investigator": { "id": 20184, "first_name": "TERRY R", "last_name": "MAGNUSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "For decades, the mouse has been the premier animal model for studies of human disease, providing the opportunity to explore experimental questions that are intractable for direct study in humans. As a result, key insights have been obtained for a variety of clinical conditions. Spurred by advances in technology and international efforts to systematically knock out all of the protein coding genes in the genome, the number of genetically engineered mice has expanded rapidly in the past 20 years. The responsibility for maintenance and distribution of mutant mice was initially placed on individual investigators, which was a tremendous burden in terms of cost, labor and space. In 1999, the NIH recognized the need for a resource to protect the investment in mutant mouse strains and ensure open access to all biomedical researchers and established the Mutant Mouse Regional Resource Centers (MMRRC). Since 1999, the central goal of the MMRRC-UNC has been to work collectively with MMRRC consortium partners to develop and maintain high standards for importation, rederivation, cryopreservation, and distribution of mutant mouse strains to biomedical investigators. The MMRRC- UNC will continue to contribute to the goals of the Consortium in the next project period by implementing the following Specific Aims devoted to continuing its successful role as a cryoarchive and distribution center and incorporating research goals that synergize with and extend the value of the resource: 1) Streamline and improve operating procedures to increase importation, distribution, and cryoarchive of mouse strains. 2) Establish, maintain, and distribute a comprehensive cryoarchive for the Collaborative Cross (CC) resource. 3) Develop and disseminate computational tools for mouse genetic QC and genomics research, which will enhance phenotypic reproducibility. 4) Investigate the interaction of genetics and environment on experimental variability and reproducibility. !", "keywords": [ "Address", "Animal Model", "Applied Research", "Archives", "Biocompatible Materials", "Biomedical Research", "California", "Caring", "Cell Separation", "Clinical", "Cloning", "Code", "Collaborations", "Communities", "Complement", "Cryopreservation", "Data", "Deposition", "Development", "Disease model", "Embryo", "Ensure", "Environment", "Fee-for-Service Plans", "Funding", "Gene Targeting", "Genes", "Genetic", "Genetic Engineering", "Genetic Research", "Genetically Engineered Mouse", "Genome", "Genomics", "Genotype", "Germ Cells", "Goals", "Health", "Human", "Human Development", "Individual", "Informatics", "International", "Investments", "Knock-out", "Maintenance", "Marketing", "Methods", "Mission", "Missouri", "Modeling", "Mouse Strains", "Mus", "Mutagenesis", "Mutant Strains Mice", "Names", "North Carolina", "Phenotype", "Policies", "Procedures", "Process", "Proteins", "Protocols documentation", "Public Health", "Quality Control", "Recovery", "Reproducibility", "Research", "Research Personnel", "Research Project Grants", "Resources", "Role", "Scientist", "Services", "Study models", "System", "Technology", "Testing", "Transgenic Organisms", "United States", "United States National Institutes of Health", "Universities", "Work", "complement resource", "computerized tools", "cost", "embryo cryopreservation", "embryonic stem cell", "gut microbiome", "high risk", "high standard", "human disease", "improved", "insight", "meetings", "member", "mouse genetics", "mouse model", "new technology", "pathogen", "preservation", "programs", "repository", "sperm quality" ], "approved": true } }, { "type": "Grant", "id": "8722", "attributes": { "award_id": "1P50MD017348-01", "title": "A Cardiometabolic Health Program LINKED with Clinical-Community Support and Mobile HEAlth TelemonitoRing in Underserved PopulaTionS (LINKED-HEARTS PROGRAM)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-24", "end_date": "2026-06-30", "award_amount": 702093, "principal_investigator": { "id": 24505, "first_name": "Yvonne", "last_name": "Commodore-Mensah", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24506, "first_name": "Cheryl", "last_name": "Dennison Himmelfarb", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Innovation in chronic disease management is urgently needed to effectively control hypertension (HTN) and diabetes, conditions which affect millions of Americans. Uncontrolled HTN and diabetes cause cardiovascular disease, stroke, chronic kidney disease (CKD), and premature death. However, these conditions are poorly controlled despite the availability of effective and affordable therapy. A pressing priority is reducing disparities in the management and control of chronic diseases and making primary care more convenient for underserved populations. Black and Hispanic adults are disproportionately affected by HTN and diabetes than White adults. They also experience more adverse social determinants of health, including a lack of access to reliable transportation and fragmented access to primary care. Team-based care including community health workers and pharmacists are “best practices” in improving HTN and diabetes control. Telehealth has become a cornerstone of efforts to minimize disruptions in primary care and can be enhanced with remote patient monitoring devices. The COVID-19 pandemic has spurred efforts to increase access to timely and appropriate care through re-engineering primary care to be patient-centered and digitally-enabled. Sphygmo Home, a remote patient telemonitoring solution that links with validated blood pressure (BP) and glucose monitoring devices is a promising solution to improve patient's self-management of HTN and diabetes. We have designed the LINKED-HEARTS Program, an innovative, theoretically derived, patient-centered, multi-level intervention to address individual and community-level social determinants that affect chronic disease management. The LINKED-HEARTS Program focuses on addressing structural issues of access and includes a self-measured BP(SMBP) and blood glucose telemonitoring platform; team-based care including a pharmacist and community health worker and provider-level interventions. Using a hybrid type I effectiveness-implementation design, our proposed specific aims are 1) To compare the effect of the LINKED-HEARTS Program versus SMBP alone in improving BP control (systolic BP<140/90 mm Hg) and improving patient-centered outcomes at 6 and 12 months, in a cluster-randomized controlled trial of adults with uncontrolled HTN and either diabetes or CKD. 2) To use the Pragmatic Robust Implementation and Sustainability Model (PRISM) to evaluate the reach, adoption, maintenance of the LINKED-HEARTS program at 12 and 24 months post-randomization and explore contextual factors that associated with adoption and maintenance of the program. We will enroll 600 adults, clustered in 16 practices including federally qualified healthcare centers. Through early and continued stakeholder engagement with health system leaders, providers, patients, and our community, we seek to close the wide “know-do-gap” and reduce chronic disease disparities. We also propose a comprehensive dissemination strategy to reach critical audiences and achieve buy-in and policy change.", "keywords": [ "Address", "Adherence", "Adoption", "Adult", "Affect", "African American", "American", "Behavioral", "Biological", "Black race", "Blood Glucose", "Blood Pressure", "Blood Pressure Monitors", "Bluetooth", "COVID-19 pandemic", "Cardiovascular Diseases", "Caring", "Cessation of life", "Chronic", "Chronic Disease", "Chronic Kidney Failure", "Clinic", "Clinical", "Communities", "Community Health Aides", "Complex", "Data", "Devices", "Diabetes Mellitus", "Disease Management", "Education", "Engineering", "Enrollment", "Ethnic group", "Glycosylated hemoglobin A", "Health", "Health Professional", "Health Services Accessibility", "Health Technology", "Health behavior", "Health system", "Healthcare", "High Prevalence", "Hispanics", "Home", "Hybrids", "Hypertension", "Improve Access", "Individual", "Intervention", "Kidney Diseases", "Latino", "Link", "Maintenance", "Measures", "Minority Groups", "Monitor", "Morbidity - disease rate", "Not Hispanic or Latino", "Organ", "Patient-Focused Outcomes", "Patients", "Persons", "Pharmacists", "Plant Roots", "Policies", "Population", "Practical Robust Implementation and Sustainability Model", "Prevalence", "Primary Health Care", "Provider", "Randomized", "Randomized Controlled Trials", "Self Management", "Soil", "Stroke", "Structure", "System", "Time", "Transportation", "Underserved Population", "Uninsured", "Visit", "Work", "base", "blood pressure regulation", "cardiometabolism", "cardiovascular disorder risk", "cardiovascular risk factor", "care delivery", "clinical decision-making", "community clinic", "contextual factors", "design", "diabetes control", "diabetes risk", "digital", "disease disparity", "disparity reduction", "dissemination strategy", "effectiveness implementation design", "ethnic minority population", "evidence based guidelines", "experience", "glucose monitor", "health care availability", "health disparity", "health equity", "high risk", "hypertension control", "improved", "innovation", "mHealth", "monitoring device", "mortality", "patient monitoring device", "patient oriented", "premature", "prevent", "primary outcome", "programs", "racial and ethnic", "racial minority", "randomized trial", "remote patient monitoring", "secondary outcome", "social", "social culture", "social determinants", "social health determinants", "telehealth", "telemonitoring" ], "approved": true } }, { "type": "Grant", "id": "6907", "attributes": { "award_id": "1R41AI167078-01", "title": "A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6606, "first_name": "Lanling", "last_name": "Zou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-01", "end_date": "2023-12-31", "award_amount": 300000, "principal_investigator": { "id": 22740, "first_name": "Christian", "last_name": "Harding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (hvKp). cKp commonly acts as an opportunistic pathogen causing disease in hospitalized or immunocompromised individuals. In fact, cKp is annually responsible for 5% of all healthcare-associated infections and is the leading cause of nosocomial pneumonia in the US. Furthermore, cKp isolates are often carbapenem-resistant (CR), limiting treatment options. In the US, K. pneumoniae multilocus sequence type 258 (ST258) strains account for ~70% of all carbapenem- resistant K. pneumoniae infections. Conversely, hvKp usually cause community-acquired infections in healthy hosts that frequently manifest as community-acquired pneumonia. Like ST258 infections, hvKp infections have high mortality rates approaching 40-60%. Currently, there are no licensed vaccines available to prevent K. pneumoniae infections and none in clinical trials. Nevertheless, preliminary data demonstrate both cKp and hvKp infections can be prevented by vaccines that target their capsular polysaccharide (CPS). Conjugate vaccines consist of a CPS covalently attached to an immunogenic carrier protein. While the clinical benefits of conjugate vaccines are well documented, the development of new conjugate vaccines targeting K. pneumoniae is lagging, likely due to the high technological barriers to entry and high costs associated with conjugate vaccine production. In addition, most conjugate vaccines are multivalent, further increasing manufacturing complexities. In order to simplify conjugate vaccine production, we have developed an in vivo conjugation platform termed bioconjugation. Bioconjugation allows for the simultaneous production of the CPS, the carrier protein and their subsequent covalent linkage all within E. coli. Key to our bioconjugation platform is our patented conjugating enzyme, PglS, which attaches virtually any polysaccharide to a unique amino acid sequence fused to the carrier protein. Furthermore, bioconjugation is modular, allowing for rapid production of multiple, different CPS-protein conjugates. Using our bioconjugation platform, we are developing a multivalent CPS-based bioconjugate vaccine to prevent the majority of K. pneumoniae infections. In this Phase I STTR program, four serotypes were initially selected (K1, K2, KL106, KL107) as these serotypes are associated with >80% of all hvKp (K1 and K2) isolates worldwide and >70% of ST258 (KL106 and KL107) isolates in the US. In Aim 1, we will produce a tetravalent (K1, K2, KL106, KL107) bioconjugate vaccine on a modified carrier protein glycosylated at an internal site, which is expected to improve conjugate characteristics such as stability and immunogenicity. In Aim 2, we will test the tetravalent bioconjugate vaccine in a dose-escalation study to determine an optimal dose. Finally, in Aim 3, we will challenge groups of placebo- or bioconjugate-vaccinated mice with either a ST258 strain (KL106 and KL107) or a hvKp strain (K1 and K2) and assess survival as a surrogate for vaccine efficacy.", "keywords": [ "Americas", "Amino Acid Sequence", "Antibiotics", "Antibody Response", "Bacterial Pneumonia", "COVID-19 patient", "COVID-19 pneumonia", "Carbapenems", "Carrier Proteins", "Cessation of life", "Characteristics", "Chemistry", "Clinical", "Clinical Trials", "Colony-forming units", "Communities", "Community-Acquired Infections", "Conjugate Vaccines", "Data", "Development", "Disease", "Dose", "Encapsulated", "Enzymes", "Escherichia coli", "Europe", "Formulation", "Genomics", "Goals", "Human", "Immunization", "Immunocompromised Host", "Immunoglobulin G", "Individual", "Infection", "Klebsiella pneumoniae", "Legal patent", "Modeling", "Multi-Drug Resistance", "Mus", "Names", "Nosocomial pneumonia", "Phase", "Pneumococcal conjugate vaccine", "Polysaccharides", "Prevnar", "Production", "Proteins", "Resistance", "Serotyping", "Site", "Small Business Technology Transfer Research", "Southern Europe", "Syndrome", "Technology", "Testing", "Vaccinated", "Vaccination", "Vaccine Production", "Vaccines", "Virulent", "base", "capsule", "carbapenem resistance", "clinically relevant", "commercialization", "community acquired pneumonia", "cost", "glycosylation", "healthcare-associated infections", "human pathogen", "immunogenic", "immunogenicity", "improved", "in vivo", "mortality", "mouse model", "opportunistic pathogen", "pathogenic bacteria", "placebo group", "prevent", "programs", "prototype", "research and development", "resistant Klebsiella pneumoniae", "vaccine access", "vaccine development", "vaccine efficacy", "virtual" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }